A clash is brewing between doctors and patients when it comes to treatment for sleep apnea in those with obesity, a new study ...

Eli Lilly’s LLY key top-line drivers are its GLP-1 medicines, Mounjaro for type II diabetes and Zepbound for obesity. Both ...

A Cleveland Clinic study shows that semaglutide and tirzepatide—injectable GLP-1 drugs for obesity—produce smaller weight ...

A new study to be presented at the SLEEP 2025 annual meeting found that sleep medicine professionals favor continuous ...

A study, which was published in The New England Journal of Medicine, found that tirzepatide (Zepbound) is more effective for ...

Early-stage study results suggest that a single shot of the company’s therapy, which works differently than GLP-1 medicines, ...

who now have another treatment option for this sleep disorder,” according to a statement from the academy. But Zepbound is only for people with obesity and sleep apnea, the AASM noted.

The huge driver of this revenue generated was thanks to the company's obesity drug Zepbound, marketed as Mounjaro for the treatment of patients with Type 2 Diabetes (T2D). There were two key ...

Eli Lilly's experimental obesity drug, eloralintide, helped some patients lose 11.5% of their body weight at 12 weeks in an ...